...
首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >FACTS ON GENERIC DRUGS TO MEET OUT WORLDWIDE CHALLENGES FOR IMPLEMENTING GENERIC MEDICINE RELATED POLICIES OF HEALTH SCHEMES
【24h】

FACTS ON GENERIC DRUGS TO MEET OUT WORLDWIDE CHALLENGES FOR IMPLEMENTING GENERIC MEDICINE RELATED POLICIES OF HEALTH SCHEMES

机译:通用药品应对实施通用药品相关卫生计划的全球挑战的事实

获取原文
           

摘要

Global market of generic drug has been propelled by new government initiatives to produce generic drugs and to promote the use of generic drugs; thus the use of generic pharmaceutical products represents over half of the total volume of pharmaceutical products used worldwide. India is the world’s largest exporter of cost effective generic medicines and leading Indian generic companies are generating more than fifty percent revenue from the export business of generic drugs. After the expiry of patent or marketing rights of the patented drug, generic drugs can be marketed. Generic drugs are available at affordable prices with assured quality and therapeutic value. The decision on drug approval is taken only after being assured of its pharmaceutically equivalent and bioequivalent properties. According to an estimate from the World Health Organization (WHO), the percentage of population without adequate access to essential medicines is less than 1% in high-income countries, 24% in middle-income countries, and 39% in low-income countries, due to their high cost. Recently Govt. of India has launched a campaign ‘Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)’ to promote the availability of generic drugs at affordable prices for all. It has also been decided to create a database of generic equivalents of branded medicine, paving the way for mandatory prescription of generic drugs along with brand names, to bring down the healthcare budget of every citizen of India. Branded versus generic medicines is an ongoing topic of debate and discussions among physicians, pharmacists, drug users, drug regulators, and policy makers across the world. Considering this aspect, the present article is an attempt to produce facts on generic drugs and focusing on the worldwide challenges through the major stakeholders of generic medicine.
机译:新的政府举措推动了非专利药物的全球市场,以生产非专利药物和促进非专利药物的使用;因此,通用药品的使用量占全球药品总使用量的一半以上。印度是全球最大的高性价比仿制药出口国,印度领先的仿制药公司正在从仿制药出口业务中获得超过50%的收入。专利药品的专利权或销售权期满后,可以销售仿制药。仿制药可以以负担得起的价格获得,并保证质量和治疗价值。只有在确定其药物等效和生物等效特性后,才能做出药物批准的决定。根据世界卫生组织(WHO)的估计,在高收入国家中,无法充分获得基本药物的人口比例不到1%,在中等收入国家中不到24%,在低收入国家中不到39% ,由于它们的成本很高。最近的政府。印度国家/地区发起了一项名为“ Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP)”的运动,目的是促进所有人以可承受的价格获得仿制药。还已决定创建一个品牌药仿制等效物数据库,为强制性处方仿制药以及商标名称铺平道路,以降低印度每个公民的医疗保健预算。品牌药与非专利药是世界各地医师,药剂师,吸毒者,药物监管者和政策制定者之间不断辩论和讨论的话题。考虑到这一方面,本文试图通过非专利药的主要利益相关者就非专利药产生事实并关注全球挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号